Table 2 Demographic profile, laboratory parameters and drug dosages during maintenance therapy of ALL children studied with and without TPMT polymorphisms

Maintenance follow-up (months)

14 (11.5-20.5)

14 (12–16)

0.782

Leucocytes (×10⁹/L)

2.7 (2.35-4.23)

3.2 (2.56-4.14)

0.597

Platelet (×10⁹/L)

265.4 (±105.8)

227.7 (±70.3)

0.286

Percentage of neutrophils

56.4 (±14.5)

55.5 (±12.9)

0.887

ANC (×10⁹/L)

1.35 (1.08-2.68)

1.84 (1.30-2.20)

0.438

AST (mg/dL)

35.0 (33.7-47.5)

46.5 (30.5-54.0)

0.528

ALT (mg/dL)

28.5 (17.5-69.0)

61.0 (22.0-84.5)

0.159

Total Bilirubin (mg/dL)

0.43 (0.35-0.7)

0.59 (0.51-0.78)

0.141

Direct Bilirubin (mg/dL)

0.12 (0.11-0.22)

0.12 (0.09-0.15)

0.314